Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.21, $0.65 worse than the analyst estimate of $0.86. Revenue for the quarter came in at $156.1 million versus the consensus estimate of $205 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.